Hospital Del Mar

The Hospital Del Mar conducts extensive research in cancer across multiple organ systems, aiming to test new targeted agents and combination regimens that improve survival and quality of life.

• Advanced non‑small cell lung cancer
• Metastatic breast cancer (including triple‑negative and HER2‑positive)
• Renal cell carcinoma
• Colorectal cancer
• Urothelial carcinoma

The program emphasizes precision medicine, biomarker‑driven enrollment, and supportive care strategies for patients with high‑risk solid tumours.

A broad portfolio of trials addresses bacterial, viral and fungal infections, evaluating novel antimicrobials, vaccine approaches and diagnostic improvements.

• Nontuberculous mycobacterial lung disease (MAC)
• Gram‑negative bacteremia and sepsis
• Invasive candidiasis and candidemia
• COVID‑19 therapeutic studies
• Respiratory viral infections in immunocompromised hosts

Research integrates antimicrobial stewardship principles and rapid diagnostic techniques to reduce morbidity and resistance.

Clinical investigations target heart disease, hypertension and lipid disorders, focusing on therapies that lower event rates and manage chronic conditions.

• Acute myocardial infarction (STEMI/NSTEMI)
• Heart failure with reduced ejection fraction
• Atherosclerotic cardiovascular disease with elevated Lp(a)
• Resistant hypertension
• Hypercholesterolemia and LDL‑C lowering strategies

The site leverages advanced imaging and biomarker profiling to personalize cardiovascular risk reduction.

Trials in the neurological field explore disease‑modifying treatments and symptom control for progressive disorders such as ALS, multiple sclerosis and Alzheimer’s disease.

• Amyotrophic lateral sclerosis (ALS)
• Relapsing‑remitting multiple sclerosis
• Early Alzheimer’s disease
• Focal onset epilepsy
• Chronic neuropathic pain syndromes

Patient‑reported outcomes and functional assessments are central to evaluating therapeutic impact.

Research at Hospital Del Mar includes kidney transplantation and a range of autoimmune conditions, seeking to improve graft tolerance and control immune dysregulation.

• Kidney transplant recipients with antibody‑mediated rejection
• Highly sensitised transplant candidates
• Immune thrombocytopenia (ITP)
• Systemic lupus erythematosus (SLE)
• Autoimmune cytopenias (wAIHA, CAD, ITP)

The program combines novel immunosuppressive regimens with biomarker monitoring to enhance long‑term graft survival.